TY  - GEN
T1  - Generated from the frozen UroLongevity Version 2.1 bibliography (evidence reviewed through 2026-08-13). Each entry preserves the exact published citation text; structured fields were NOT decomposed, to avoid altering the frozen citations. DOI, PMID, and source URLs are carried verbatim where supplied.
ER  - 

TY  - GEN
ID  - ULON-REF-0001
TI  - Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr 2011;53:183-189.
AU  - Adunsky
PY  - 2011
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0002
TI  - Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26:178. doi:10.1007/s10522-025-10315-x.
AU  - Al-Dulaimi
PY  - 2025
DO  - 10.1007/s10522-025-10315-x
UR  - https://doi.org/10.1007/s10522-025-10315-x
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0003
TI  - Araj M, Brzezik M, Mądra-Gackowska K, Szeleszczuk Ł. Epitalon — 25 years of research. Int J Mol Sci 2025.
AU  - Araj
PY  - 2025
UR  - https://www.mdpi.com/1422-0067/26/6/2691
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0004
TI  - Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36.
AU  - Aronne
PY  - 2025
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0005
TI  - Badenhorst T, Svirskis D, Wu Z. Pharmaceutical strategies for the topical dermal delivery of peptides/proteins for cosmetic and therapeutic applications. Austin J Pharmacol Ther 2016;4:1083.
AU  - Badenhorst
PY  - 2016
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0006
TI  - Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23:1060-1065. doi:10.1016/j.cmet.2016.05.011.
AU  - Barzilai
PY  - 2016
DO  - 10.1016/j.cmet.2016.05.011
UR  - https://doi.org/10.1016/j.cmet.2016.05.011
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0007
TI  - Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013;14:542-559.
AU  - Bauer
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0008
TI  - Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29:1527-1534.
AU  - Beck
PY  - 2014
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0009
TI  - Bell CG, Lowe R, Adams PD, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol 2019;20:249.
AU  - Bell
PY  - 2019
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0010
TI  - Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife 2022;11:e73420.
AU  - Belsky
PY  - 2022
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0011
TI  - Ben-Shlomo A, Deng N, Ding E, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J Clin Invest 2020;130:5738-5755.
AU  - Ben-Shlomo
PY  - 2020
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0012
TI  - Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med 2020;26:964-973.
AU  - Berry
PY  - 2020
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0013
TI  - Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010;11:35-46.
AU  - Bjedov
PY  - 2010
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0014
TI  - Bliss M. The Discovery of Insulin. University of Chicago Press; 1982.
AU  - Bliss
PY  - 1982
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0015
TI  - Bock-Marquette I, Saxena A, White MD, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432:466-472.
AU  - Bock-Marquette
PY  - 2004
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0016
TI  - Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101:364-389.
AU  - Bornstein
PY  - 2016
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0017
TI  - Brakedal B, Dölle C, Riemer F, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab 2022;34:396-407.e6.
AU  - Brakedal
PY  - 2022
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0018
TI  - Brea-Gómez B, Pérez-Llanes R, Ortega-Donaire L, et al. Effectiveness of pelvic floor muscle training with biofeedback in patients undergoing radical prostatectomy: systematic review and meta-analysis. Eur Urol Focus 2025; published online ahead of print.
AU  - Brea-Gómez
PY  - 2025
UR  - https://pubmed.ncbi.nlm.nih.gov/40318944/
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0019
TI  - Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med 2022;387:1547-1556. (NordICC trial.)
AU  - Bretthauer
PY  - 2022
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0020
TI  - Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J. 2018;39:2401-2408. doi:10.1093/eurheartj/ehy217.
AU  - Budoff
PY  - 2018
DO  - 10.1093/eurheartj/ehy217
UR  - https://doi.org/10.1093/eurheartj/ehy217
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0021
TI  - Cohen PA, Bass S. Injecting safety into supplements — modernizing the dietary supplement law. N Engl J Med 2019;381:2387-2389.
AU  - Cohen
PY  - 2019
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0022
TI  - Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992;75:530-535.
AU  - Corpas
PY  - 1992
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0023
TI  - Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16-31. Correction: Age Ageing. 2019;48:601. doi:10.1093/ageing/afy169.
AU  - Cruz-Jentoft
PY  - 2019
DO  - 10.1093/ageing/afy169
UR  - https://doi.org/10.1093/ageing/afy169
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0024
TI  - Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-178.
AU  - Dalmasso
PY  - 2008
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0025
TI  - de Lima Beltrão FE, Carvalhal G, de Almeida Beltrão DC, et al. Treatment Preferences in Patients With Hypothyroidism. J Clin Endocrinol Metab. 2025;110(3):887-900. doi:10.1210/clinem/dgae651.
AU  - de Lima Beltrão
PY  - 2025
DO  - 10.1210/clinem/dgae651
UR  - https://doi.org/10.1210/clinem/dgae651
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0026
TI  - Dietary Supplement Health and Education Act of 1994, Pub L No. 103-417, 108 Stat 4325 (codified at 21 USC §§ 321 et seq.).
AU  - United States Congress
PY  - 1994
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0027
TI  - Drug Quality and Security Act, Pub L No. 113-54 (2013).
AU  - United States Congress
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0028
TI  - Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7:452-461. doi:10.1016/S2213-8587(19)30093-2.
AU  - Gong
PY  - 2019
DO  - 10.1016/S2213-8587(19)30093-2
UR  - https://doi.org/10.1016/S2213-8587(19)30093-2
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0029
TI  - Eli Lilly and Company. Lilly’s retatrutide reduced body weight by 28.7% in adults living with obesity and knee osteoarthritis in pivotal Phase 3 TRIUMPH-4 study. Press release, December 11, 2025.
AU  - Eli Lilly and Company
PY  - 2025
UR  - https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0030
TI  - Endocrine Society. Testosterone therapy for hypogonadism guideline resources. Clinical practice guideline, current webpage accessed August 13, 2026.
AU  - Endocrine Society
PY  - 2026
UR  - https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0031
TI  - Endocrine Society. Statement on testosterone replacement therapy. July 16, 2026.
AU  - Endocrine Society
PY  - 2026
UR  - https://www.endocrine.org/news-and-advocacy/news-room/2026/statement-on-testosterone-replacement-therapy
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0032
TI  - Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-7405.
AU  - Eng
PY  - 1992
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0033
TI  - Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;378:e34.
AU  - Estruch
PY  - 2018
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0034
TI  - Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-2370.
AU  - Falutz
PY  - 2007
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0035
TI  - Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95:4291-4304.
AU  - Falutz
PY  - 2010
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0036
TI  - Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010;53:311-322.
AU  - Falutz
PY  - 2010
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0037
TI  - Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes (Rybelsus). News release, September 20, 2019.
AU  - Food and Drug Administration
PY  - 2019
UR  - https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0038
TI  - Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act: nomination categories and interim enforcement policy. Current agency webpage, accessed August 13, 2026.
AU  - Food and Drug Administration
PY  - 2026
UR  - https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0039
TI  - Food and Drug Administration. Certain bulk drug substances for use in compounding may present significant safety risks. Current agency webpage, accessed August 13, 2026.
AU  - Food and Drug Administration
PY  - 2026
UR  - https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0040
TI  - Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Updated through May 31, 2026; accessed August 13, 2026.
AU  - Food and Drug Administration
PY  - 2026
UR  - https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0041
TI  - Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting materials, including FDA introductory and substance-specific briefing documents for BPC-157, emideltide, epitalon, KPV, MOTS-c, Semax, and TB-500. Accessed August 13, 2026.
AU  - Food and Drug Administration
PY  - 2026
UR  - https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0042
TI  - Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. Drug safety communication, February 28, 2025.
AU  - Food and Drug Administration
PY  - 2025
UR  - https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0043
TI  - Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol (Lipfendra). News release, 2026.
AU  - Food and Drug Administration
PY  - 2026
UR  - https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0044
TI  - Food and Drug Administration. FDA approves treatment for metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. News release, 2025; ongoing accelerated-approval confirmatory study status accessed August 13, 2026.
AU  - Food and Drug Administration
PY  - 2025
UR  - https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0045
TI  - Food and Drug Administration. Drug Trials Snapshot: Forzinity (elamipretide). September 2025; accelerated-approval confirmatory study status accessed August 13, 2026.
AU  - Food and Drug Administration
PY  - 2025
UR  - https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0046
TI  - Food and Drug Administration. Interim category 2 of the 503A Bulks List. Federal Register, September 29, 2023.
AU  - Food and Drug Administration
PY  - 2023
UR  - https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0047
TI  - Food and Drug Administration. Removal of certain bulk drug substances from interim category 2 of the 503A Bulks List. Federal Register, April 15, 2026.
AU  - Food and Drug Administration
PY  - 2026
UR  - https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0048
TI  - Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503-515.
AU  - Frías
PY  - 2021
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0049
TI  - Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679. doi:10.1016/S0140-6736(06)69701-8.
AU  - Lindström
PY  - 2006
DO  - 10.1016/S0140-6736(06)69701-8
UR  - https://doi.org/10.1016/S0140-6736(06)69701-8
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0050
TI  - Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199-207.
AU  - Gelbard
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0051
TI  - Goldstein AL, Low TLK, McAdoo M, et al. Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A 1977;74:725-729.
AU  - Goldstein
PY  - 1977
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0052
TI  - Grönberg A, Mahlapuu M, Ståhle M, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 2014;22:613-621.
AU  - Grönberg
PY  - 2014
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0053
TI  - Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. J Dermatolog Treat 2022;33:62-72.
AU  - Gupta
PY  - 2022
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0054
TI  - Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell 2013;49:359-367.
AU  - Hannum
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0055
TI  - Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300.
AU  - Harman
PY  - 1956
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0056
TI  - Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392-395.
AU  - Harrison
PY  - 2009
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0057
TI  - Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine 2019;47:446-456.
AU  - Hickson
PY  - 2019
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0058
TI  - HLB Therapeutics. European Phase 3 SEER-3 topline results for RGN-259 in neurotrophic keratopathy. Company notice, June 24, 2025; independent coverage published July 1, 2025.
AU  - HLB Therapeutics
PY  - 2025
UR  - https://filecache.investorroom.com/mr5ir_regenerx_ir/215/Letter%20to%20Stockholders%206-24-2025.pdf
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0059
TI  - Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025;69(5):e250093. doi:10.20945/2359-4292-2025-0093.
AU  - Hohl
PY  - 2025
DO  - 10.20945/2359-4292-2025-0093
UR  - https://doi.org/10.20945/2359-4292-2025-0093
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0060
TI  - Hohl A, Marques P, Ronsoni MF, et al. Selective estrogen receptor modulators (SERMs) for male hypogonadism: a meta-analysis of randomized controlled trials. Arch Endocrinol Metab 2025; published online ahead of print.
AU  - Hohl
PY  - 2025
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0061
TI  - Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet 2018;19:371-384.
AU  - Horvath
PY  - 2018
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0062
TI  - Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 2013;14:R115.
AU  - Horvath
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0063
TI  - Hróbjartsson A, Thomsen ASS, Emanuelsson F, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012;344:e1119.
AU  - Hróbjartsson
PY  - 2012
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0064
TI  - Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. Ann Intern Med 2013;158:781-790.
AU  - Hughes
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0065
TI  - Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287-1297. (Cologuard pivotal trial.)
AU  - Imperiale
PY  - 2014
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0066
TI  - Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006;91:4792-4797.
AU  - Ionescu
PY  - 2006
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0067
TI  - Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-216.
AU  - Jastreboff
PY  - 2022
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0068
TI  - Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med 2023;389:514-526.
AU  - Jastreboff
PY  - 2023
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0069
TI  - Kaeberlein TL, Green AS, Haddad G, et al. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. GeroScience 2023;45:2757-2768.
AU  - Kaeberlein
PY  - 2023
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0070
TI  - Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A 2020;117:29959-29967.
AU  - Kawai
PY  - 2020
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0071
TI  - Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003;135:590-592.
AU  - Khavinson
PY  - 2003
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0072
TI  - Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters 2003;24:233-240.
AU  - Khavinson
PY  - 2003
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0073
TI  - Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-1479.
AU  - Khorram
PY  - 1997
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0074
TI  - Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019;134:899-908. (RECONNECT-1 and RECONNECT-2.)
AU  - Kingsberg
PY  - 2019
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0075
TI  - Klier S, Dananberg J, Masaki L, et al. Safety and efficacy of senolytic UBX1325 in diabetic macular edema. NEJM Evidence 2025;4:EVIDoa2400009.
AU  - Klier
PY  - 2025
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0076
TI  - Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol 1986;15:836-859.
AU  - Kligman
PY  - 1986
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0077
TI  - Kokkinos P, Faselis C, Samuel IBH, et al. Cardiorespiratory fitness and mortality risk across the spectra of age, race, and sex. J Am Coll Cardiol 2022;80:598-609.
AU  - Kokkinos
PY  - 2022
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0078
TI  - Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-1084.
AU  - Kosiborod
PY  - 2023
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0079
TI  - Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21:443-454.
AU  - Lee
PY  - 2015
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0080
TI  - Lehallier B, Gate D, Schaum N, et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med 2019;25:1843-1850.
AU  - Lehallier
PY  - 2019
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0081
TI  - Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet 2015;386:266-273.
AU  - Leong
PY  - 2015
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0082
TI  - Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY) 2018;10:573-591. (PhenoAge.)
AU  - Levine
PY  - 2018
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0083
TI  - Lincoff AM, Bhasin S, Flevaris P, et al; TRAVERSE Study Investigators. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 2023;389:107-117.
AU  - Lincoff
PY  - 2023
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0084
TI  - Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-2232.
AU  - Lincoff
PY  - 2023
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0085
TI  - Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-115.
AU  - Liu
PY  - 2007
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0086
TI  - Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396:413-446.
AU  - Livingston
PY  - 2020
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0087
TI  - Low TLK, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A 1981;78:1162-1166.
AU  - Low
PY  - 1981
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0088
TI  - Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY) 2019;11:303-327.
AU  - Lu
PY  - 2019
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0089
TI  - Lucente V, MacDiarmid S, Khera M, et al. Two-year results from a prospective, multicenter, single-arm pivotal study of an implantable tibial neuromodulation system for the treatment of urinary urgency incontinence. Urology 2024;186:80-87.
AU  - Lucente
PY  - 2024
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0090
TI  - Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033.
AU  - Lundh
PY  - 2017
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0091
TI  - López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell 2023;186:243-278.
AU  - López-Otín
PY  - 2023
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0092
TI  - López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194-1217.
AU  - López-Otín
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0093
TI  - Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391:1193-1205.
AU  - Malhotra
PY  - 2024
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0094
TI  - Mandsager K, Harb S, Cremer P, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open 2018;1:e183605.
AU  - Mandsager
PY  - 2018
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0095
TI  - Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014;6:268ra179.
AU  - Mannick
PY  - 2014
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0096
TI  - Mannick JB, Morris M, Hockey HU, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 2018;10:eaaq1564.
AU  - Mannick
PY  - 2018
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0097
TI  - Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368.
AU  - Manson
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0098
TI  - Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844.
AU  - Marso
PY  - 2016
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0099
TI  - Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322.
AU  - Marso
PY  - 2016
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0100
TI  - Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults. Nat Commun 2018;9:1286.
AU  - Martens
PY  - 2018
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0101
TI  - McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun 2024;15:5046.
AU  - McDermott
PY  - 2024
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0102
TI  - McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016;375:919-931.
AU  - McEvoy
PY  - 2016
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0103
TI  - Merrifield RB. Solid phase peptide synthesis I: The synthesis of a tetrapeptide. J Am Chem Soc 1963;85:2149-2154. (Nobel Prize in Chemistry, 1984.)
AU  - Merrifield
PY  - 1963
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0104
TI  - MESA Investigators — see Budoff MJ et al. (above) for the contemporary CAC-mortality framework citation.
AU  - MESA Investigators
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0105
TI  - Moel M, Harinath G, Lee V, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY) 2025;17:908-936.
AU  - Moel
PY  - 2025
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0106
TI  - Nadon NL, Strong R, Miller RA, Harrison DE. NIA Interventions Testing Program: investigating putative aging intervention agents in a genetically heterogeneous mouse model. eBioMedicine 2017;21:3-4.
AU  - Nadon
PY  - 2017
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0107
TI  - Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1647-1659.
AU  - Nair
PY  - 2006
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0108
TI  - Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008;149:601-611.
AU  - Nass
PY  - 2008
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0109
TI  - Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255-2263.
AU  - Ngandu
PY  - 2015
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0110
TI  - Nicholls SJ, Bhatt DL, Buse JB, et al; SURPASS-CVOT Investigators. Cardiovascular efficacy and safety of tirzepatide in patients with type 2 diabetes and atherosclerotic cardiovascular disease. N Engl J Med 2025;393:2347-2358.
AU  - Nicholls
PY  - 2025
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0111
TI  - Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-1105.
AU  - Nishihara
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0112
TI  - Nobel Assembly at Karolinska Institutet. The Nobel Prize in Physiology or Medicine 2009: Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak. October 5, 2009.
AU  - Nobel Assembly at Karolinska Institutet
PY  - 2009
UR  - https://www.nobelprize.org/prizes/medicine/2009/press-release/
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0113
TI  - Novo Nordisk. Evoke and evoke+ trials of oral semaglutide in early Alzheimer’s disease did not meet primary endpoint. Press release, November 24, 2025.
AU  - Novo Nordisk
PY  - 2025
UR  - https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916462
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0114
TI  - Ocampo A, Reddy P, Martinez-Redondo P, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell 2016;167:1719-1733.e12.
AU  - Ocampo
PY  - 2016
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0115
TI  - Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med 2012;367:1969-1972.
AU  - Outterson
PY  - 2012
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0116
TI  - Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093. doi:10.1001/jama.289.16.2083.
AU  - Appel
PY  - 2003
DO  - 10.1001/jama.289.16.2083
UR  - https://doi.org/10.1001/jama.289.16.2083
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0117
TI  - Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705. doi:10.1056/NEJMoa1814052.
AU  - Mack
PY  - 2019
DO  - 10.1056/NEJMoa1814052
UR  - https://doi.org/10.1056/NEJMoa1814052
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0118
TI  - Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A 1995;92:7001-7005.
AU  - Patchett
PY  - 1995
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0119
TI  - Paulescu NC. Recherche sur le rôle du pancréas dans l’assimilation nutritive. Arch Int Physiol 1921;17:85-103.
AU  - Paulescu
PY  - 1921
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0120
TI  - Penha MÁ, Miot HA, Kasprzak M, et al. Oral minoxidil 5 mg daily versus topical minoxidil 5% twice daily for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol 2024;160:600-605.
AU  - Penha
PY  - 2024
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0121
TI  - Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013;177:1006-1014.
AU  - Peppard
PY  - 2013
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0122
TI  - Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109-121.
AU  - Perkovic
PY  - 2024
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0123
TI  - Perls TT, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for “antiaging”: clinical and legal issues. JAMA 2005;294:2086-2090.
AU  - Perls
PY  - 2005
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0124
TI  - Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010;183:1438-1443.
AU  - Peters
PY  - 2010
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0125
TI  - Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.
AU  - Pi-Sunyer
PY  - 2015
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0126
TI  - Pickart L, Thaler MM. Growth-modulating tripeptide (glycyl-histidyl-lysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. J Cell Physiol 1980;102:129-139.
AU  - Pickart
PY  - 1980
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0127
TI  - Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015;2015:648108.
AU  - Pickart
PY  - 2015
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0128
TI  - Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-1026.
AU  - Radley
PY  - 2006
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0129
TI  - Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552-561.
AU  - Raun
PY  - 1998
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0130
TI  - Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med 2021;23:471-478. (TAZPOWER trial.)
AU  - Reid Thompson
PY  - 2021
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0131
TI  - Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021;12:470.
AU  - Reynolds
PY  - 2021
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0132
TI  - Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-4239.
AU  - Romani
PY  - 2004
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0133
TI  - Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008;179:1066-1071.
AU  - Safarinejad
PY  - 2008
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0134
TI  - Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089-2099.
AU  - Sanyal
PY  - 2025
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0135
TI  - Savin MJ, Wang H, Pei H, et al. Association of a pace of aging epigenetic clock with rate of cognitive decline in the Framingham Heart Study Offspring Cohort. Alzheimers Dement (Amst). 2024;16(4):e70038. doi:10.1002/dad2.70038.
AU  - Savin
PY  - 2024
DO  - 10.1002/dad2.70038
UR  - https://doi.org/10.1002/dad2.70038
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0136
TI  - Schmauck-Medina T, Molière A, Lautrup S, et al. New hallmarks of ageing: a 2022 Copenhagen ageing meeting summary. Aging (Albany NY) 2022;14:6829-6839.
AU  - Schmauck-Medina
PY  - 2022
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0137
TI  - Schweiger A, Diniz B, Nicol G, et al. Protocol for a pilot clinical trial of the senolytic drug combination dasatinib plus quercetin to mitigate age-related health and cognitive decline in mental disorders. F1000Res. 2025;13:1072. doi:10.12688/f1000research.151963.2.
AU  - Schweiger
PY  - 2025
DO  - 10.12688/f1000research.151963.2
UR  - https://doi.org/10.12688/f1000research.151963.2
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0138
TI  - Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 1993;87:313-327.
AU  - Sikiric
PY  - 1993
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0139
TI  - Simon JA, Kingsberg SA, Goldstein I, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019;134:909-917.
AU  - Simon
PY  - 2019
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0140
TI  - Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Int J Mol Sci 2023;24:554.
AU  - Sosne
PY  - 2023
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0141
TI  - Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6:e821-e830.
AU  - Stanley
PY  - 2019
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0142
TI  - Stealth BioTherapeutics Inc. Stealth BioTherapeutics announces FDA accelerated approval of Forzinity (elamipretide HCl), the first therapy for progressive and life-limiting ultra-rare genetic disease Barth syndrome. Press release, September 19, 2025.
AU  - Stealth BioTherapeutics Inc
PY  - 2025
UR  - https://stealthbt.com/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl-the-first-therapy-for-progressive-and-life-limiting-ultra-rare-genetic-disease-barth-syndrome/
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0143
TI  - Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med 2017;376:2534-2544. (TRUST trial.)
AU  - Stott
PY  - 2017
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0144
TI  - Talpos S. How a Croatian Lab Spawned a Buzzy Peptide Now Popular With MAHA. Undark. February 3, 2026. Co-published by STAT.
AU  - Talpos
PY  - 2026
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0145
TI  - Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91:799-805.
AU  - Teichman
PY  - 2006
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0146
TI  - The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause 2022;29:767-794.
AU  - North American Menopause Society Advisory Panel
PY  - 2022
UR  - https://menopause.org/professional-resources/position-statements
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0147
TI  - U.S. Department of Justice. Nicholasville compounding pharmacy and its owner plead guilty to unlawful distribution of prescription drugs. Press release, October 5, 2020. (Tailor Made Compounding LLC.)
AU  - U.S. Department of Justice
PY  - 2020
UR  - https://www.justice.gov/usao-edky/pr/nicholasville-compounding-pharmacy-and-its-owner-plead-guilty-unlawful-distribution
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0148
TI  - McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18:611-619. doi:10.1007/s12178-025-09990-7.
AU  - McGuire
PY  - 2025
DO  - 10.1007/s12178-025-09990-7
UR  - https://doi.org/10.1007/s12178-025-09990-7
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0149
TI  - Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012;280:22-35.
AU  - Vandamme
PY  - 2012
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0150
TI  - Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96.
AU  - Vittone
PY  - 1997
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0151
TI  - Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 2022;7:48.
AU  - Wang
PY  - 2022
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0152
TI  - Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877-888. doi:10.1056/NEJMoa2302392.
AU  - Wharton
PY  - 2023
DO  - 10.1056/NEJMoa2302392
UR  - https://doi.org/10.1056/NEJMoa2302392
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0153
TI  - Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002.
AU  - Wilding
PY  - 2021
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0154
TI  - Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med 2018;24:1246-1256.
AU  - Xu
PY  - 2018
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0155
TI  - Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687-696. doi:10.1056/NEJMoa1100370.
AU  - Zauber
PY  - 2012
DO  - 10.1056/NEJMoa1100370
UR  - https://doi.org/10.1056/NEJMoa1100370
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0156
TI  - Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell 2015;163:1079-1094.
AU  - Zeevi
PY  - 2015
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0157
TI  - Zhang YY, Chen EQ, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009;6:63.
AU  - Zhang
PY  - 2009
N1  - UroLongevity v2.1 frozen bibliography
ER  - 

TY  - GEN
ID  - ULON-REF-0158
TI  - Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015;14:644-658.
AU  - Zhu
PY  - 2015
N1  - UroLongevity v2.1 frozen bibliography
ER  -